drugset / Trial / NCT02597946
Afatinib in NSCLC With HER2 Mutation
NaSingle-groupOpen-labelTreatment
Summary
to investigate effectiveness and safety of afatinib in the advanced NSCLC patients with HER2 mutations, previously treated with 1 or 2 chemotherapy regimens
Timeline
- Start
- 2016-03-18
- Primary completion
- 2018-07-22
- Completion
- 2018-07-22
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Afatinib | Small molecule | — | — |
| Background | Paclitaxel | Small molecule | — | — |